Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2018.12.17
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
PDF (244 KB)
2018.12.10
Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel ...
PDF (313 KB)
2019.04.09
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Tre ...
PDF (186 KB)
2019.04.04
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with ...
PDF (168 KB)
2019.09.09
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...
PDF (261 KB)
2019.08.21
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...
PDF (297 KB)
2019.11.04
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
2019.02.05
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartin ...
PDF (190 KB)
2019.06.18
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...
PDF (153 KB)
2019.05.15
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and P ...
PDF (177 KB)
Showing 1 - 10 of 37 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...